After a seismic Round 4, which saw Scotland stun France and Italy claim a historic first-ever victory over England, the Championship title has become a three-horse race heading into "Super Saturday." ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

In my book, Spoiled, I engage with a group of contemporary Asian American artists who expose and unravel the expectation that their work should heal and repair the wounds of racial difference as ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...